Rationale: Learning about the long-term effects of dietary, lifestyle, and environmental factors on the risk of cancer progression and recurrence may help the study of bladder cancer in the future.Purpose: This clinical trial is studying how dietary, lifestyle, and environmental factors affect patients with early-stage bladder cancer. 

Official Title

Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial).


  • Bladder Cancer

Study Type


Study Design

Further Details


  • To examine if common and potentially modifiable dietary, lifestyle, and environmental exposures affect the risk of recurrence and progression in bladder cancer.


  • This is a multicenter study.
  • Detailed information will be collected about the patients’ lifestyle and their exposure to risk factors associated with bladder cancer using semi-structured questionnaires. A baseline questionnaire will be administered at the time of diagnosis and will collect information about socio-demographics, environmental exposures, medical history, diet, health-related quality of life, and social support.
  • Further questionnaires will be administered at regular follow-up visits to capture information relating to changes in exposure. A postal questionnaire will be used to collect historical information that may require the patient to check records or consult family or friends. Patients will also be asked to keep a 1-week food, fluid, and micturition diary.
  • Patients continue to complete questionnaires at 3 months and then annually for up to 5 years.
  • Peer Reviewed and Funded or Endorsed by Cancer Research UK.

Study Start

December 2005

Eligibility & Criteria

  • Ages Eligible for Study: 18 Years and older
  • Genders Eligible for Study: Both
  • Accepts Healthy Volunteers: No

Inclusion criteria:

  • Enrolled on parent protocol CRUK-BCPP-2005-01
  • Bladder lesion with cystoscopic characteristics compatible with urothelial cancer or transitional cell carcinoma
  • Histologically proven urothelial cancer meeting one of the following criteria:
  • Stage Ta (WHO grade 2/3, or grade 1 tumors that are either multifocal or > 3 cm in size)
  • Stage T1 (any grade)
  • Stage Tis

Exclusion criteria:

  • Solitary grade 1 pTa tumors
  • Previous diagnosis of cancer of the urethra, bladder, ureter, or renal pelvis within the 10 years prior to current diagnosis.

Inclusion criteria:

  • Fit for cystoscopy and surgical biopsy/resection

Exclusion criteria:

  • HIV infection
  • Any condition that, in the opinion of the local investigator, might interfere with the safety of the patient or evaluation of the study objectives

Pior Concurrant Therapy:

  • Not specified

Total Enrolment


Contact Details

KK Cheng, MD     
University Hospital Birmingham


Queen Elizabeth Hospital
University Hospital of Birmingham NHS Trust
Birmingham, England, United Kingdom, B15 2TH

All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.